Advertisement

Antibody Therapy in Follicular Lymphoma

  • J. C. VillasboasEmail author
  • Grzegorz S. Nowakowski
Chapter

Abstract

Monoclonal antibodies (mAb) are critical pieces in the current management of follicular lymphoma and the vast majority of lymphoid malignancies. While most practitioners are very familiar with the use of these drugs, many are not aware that the trajectory of mAb drug development was largely based on studies done in patients with follicular lymphoma. Starting with the approval of rituximab, the first monoclonal antibody for the treatment of human cancer, monoclonal antibodies continue to evolve and influence the field of oncology as a whole. In this chapter, we examine the studies supporting the use of mAb in follicular lymphoma and reconstruct the chronological landmarks that shaped our current management of this disease. Our review will focus on clinical studies using molecules targeting CD20, CD19, CD22, and antibody-drug conjugates used alone or in combination with standard cytotoxic chemotherapy.

Keywords

Follicular lymphoma Monoclonal antibodies Anti-CD20 antibodies Anti-CD19 antibodies Anti-CD22 antibodies Rituximab Obinutuzumab Ofatumumab Epratuzumab Antibody-drug conjugates 

References

  1. 1.
    Salles G, Barrett M, Foà R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther [Internet]. 2017;34:2232–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28983798.CrossRefGoogle Scholar
  2. 2.
    Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood [Internet]. 1997;90:2188–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9310469.CrossRefGoogle Scholar
  3. 3.
    Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol [Internet]. 1997;15:3266–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9336364.CrossRefGoogle Scholar
  4. 4.
    Tobinai K, Kobayashi Y, Narabayashi M, Ogura M, Kagami Y, Morishima Y, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 1998;9:527–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9653494.CrossRefGoogle Scholar
  5. 5.
    McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol [Internet]. 1998;16:2825–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9704735.CrossRefGoogle Scholar
  6. 6.
    Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol [Internet]. 1999;17:1851–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10561225.CrossRefGoogle Scholar
  7. 7.
    Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol [Internet]. 2000;79:493–500. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11043420.CrossRefGoogle Scholar
  8. 8.
    Foran JM, Gupta RK, Cunningham D, Popescu RA, Goldstone AH, Sweetenham JW, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol [Internet]. 2000;109:81–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10848785.CrossRefGoogle Scholar
  9. 9.
    Piro LD, White CA, Grillo-López AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 1999;10:655–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10442187.CrossRefGoogle Scholar
  10. 10.
    Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood [Internet]. 2000;95:3052–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10807768.CrossRefGoogle Scholar
  11. 11.
    Hainsworth JD, Litchy S, Burris HA, Scullin DC, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol [Internet]. 2002;20:4261–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12377971.CrossRefGoogle Scholar
  12. 12.
    Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood [Internet]. 2001;97:101–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11133748.CrossRefGoogle Scholar
  13. 13.
    Colombat P, Brousse N, Salles G, Morschhauser F, Brice P, Soubeyran P, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2012;23:2380–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22782332.CrossRefGoogle Scholar
  14. 14.
    Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol [Internet]. 2005;23:1103–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15657404.CrossRefGoogle Scholar
  15. 15.
    Ghielmini M, Schmitz SH, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood [Internet]. 2004;103:4416–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14976046.CrossRefGoogle Scholar
  16. 16.
    Martinelli G, Schmitz S-FH, Utiger U, Cerny T, Hess U, Bassi S, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol [Internet]. 2010;28:4480–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20697092.CrossRefGoogle Scholar
  17. 17.
    Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol [Internet]. Elsevier Ltd. 2014;15:424–435. Available from:  https://doi.org/10.1016/S1470-2045(14)70027-0.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood [Internet]. 2016;127:2804–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26994147.CrossRefGoogle Scholar
  19. 19.
    Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol [Internet]. 1999;17:268–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10458242.CrossRefGoogle Scholar
  20. 20.
    Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell. Blood [Internet]. 2004;104:3064–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15284112.CrossRefGoogle Scholar
  21. 21.
    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood [Internet]. 2005;105:1417–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15494430.CrossRefGoogle Scholar
  22. 22.
    Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol [Internet]. 2008;26:4579–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18662969.CrossRefGoogle Scholar
  23. 23.
    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood [Internet]. 2005;106:3725–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16123223.CrossRefGoogle Scholar
  24. 24.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol [Internet]. 2013;31:1506–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23530110.CrossRefGoogle Scholar
  25. 25.
    Forstpointner R, Unterhalt M, Dreyling M, Böck H, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular. Blood [Internet]. 2006;108:4003–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16946304.CrossRefGoogle Scholar
  26. 26.
    van Oers MHJ, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood [Internet]. 2006;108:3295–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16873669.CrossRefGoogle Scholar
  27. 27.
    van Oers MHJ, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol [Internet]. 2010;28:2853–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20439641.CrossRefGoogle Scholar
  28. 28.
    Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol [Internet]. 2009;27:1607–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16873669.CrossRefGoogle Scholar
  29. 29.
    Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet (London, England) [Internet]. 2011;377:42–51. Available from: http://mayoweb.mayo.edu/hps-chemo/non-study/hematology/lymphoma/06-22-16.pdf.CrossRefGoogle Scholar
  30. 30.
    Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol [Internet]. 2014;32:3096–102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25154829.CrossRefGoogle Scholar
  31. 31.
    Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell - mediated B-cell cytotoxicity. Blood. 2010;115:4393–402.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117:4519–29.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119:5126–32.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Sehn LH, Assouline SE, D a S, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119:5118–25.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Ogura M, Tobinai K, Hatake K, Uchida T, Suzuki T, Kobayashi Y, et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2013;104:105–10.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122:1137–43.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol [Internet]. 2015;33:3467–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26282650.CrossRefGoogle Scholar
  39. 39.
    Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol [Internet]. 2016;17:1081–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27345636.CrossRefGoogle Scholar
  40. 40.
    Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med [Internet]. 2017;377:1331–1344. Available from:  https://doi.org/10.1056/NEJMoa1614598.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood [Internet]. 2008;111:5486–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18390837.CrossRefGoogle Scholar
  42. 42.
    Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol [Internet]. 2012;157:438–45. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22409295.CrossRefGoogle Scholar
  43. 43.
    Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood [Internet]. 2012;119:3698–704. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22389254.CrossRefGoogle Scholar
  44. 44.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008;68:8049–57.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Zalevsky J, Leung IWL, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR, et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood. 2009;113:3735–43.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115:1204–13.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kellner C, Zhukovsky EA, Pötzke A, Brüggemann M, Schrauder A, Schrappe M, et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia. 2013;27:1595–8.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, et al. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124:3553–60.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335:213–22.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Ward E, Mittereder N, Kuta E, Sims GP, Bowen MA, Dall’Acqua W, et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol. 2011;155:426–37.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3051–9.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:5044–51.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:3880–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Leonard JP, Schuster SJ, Emmanouilides C, Couture F, Teoh N, Wegener WA, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer. 2008;113:2714–23.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Grant BW, Jung S-H, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013;119:3797–804.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Younes A, Kim S, Romaguera J, Copeland A, Farial SDC, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012;30:2776–82.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014;20:213–20.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J Clin Oncol. 2010;28:2085–93.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of HematologyMayo ClinicRochesterUSA

Personalised recommendations